BREATHE 2 Clinic Stop-Smoking Treatment Outreach Study

Sponsor
University of Wisconsin, Madison (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05683821
Collaborator
National Cancer Institute (NCI) (NIH)
12,000
2
24

Study Details

Study Description

Brief Summary

The purpose of this research study is to see if offering adult primary care patients who smoke combustible cigarettes more frequent outreach, more choices about how they receive that outreach, and more smoking treatment options will increase the use of smoking treatments and help more people quit smoking, when compared against a standard outreach approach. Only patients at participating adult primary care clinics will be eligible for the study. Five clinic sites will be randomized to an enhanced outreach approach, while another 5 will be randomly assigned to standard smoking treatment outreach. Eligible patients at these clinics will be in this study for up to 18 months.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Text message smoking treatment
  • Drug: Nicotine replacement therapy sampling
  • Combination Product: Wisconsin Tobacco QuitLine Referral
  • Combination Product: Referral to Primary Care Provider
  • Combination Product: BREATHE 2 Cessation Study
  • Behavioral: Additional modalities to learn about and request treatment
N/A

Detailed Description

This 2-arm cluster-randomized clinical trial will compare a standard approach to smoking cessation treatment outreach in adult primary care to an enhanced approach offering more frequent outreach, multiple ways to request treatment, and a broader array of treatment options.

The researchers hypothesize that enhanced outreach comprising quarterly messages offering both standard, person-to-person treatment options (quitline services, care from a primary care provider, phone coaching and medication through a clinical trial) and self-guided treatment options (nicotine replacement therapy sampling (2 week supplies of nicotine replacement therapies and/or enrollment in text-message based cessation support via Smokefree.gov text-message programs) will attract more adult primary care patients who smoke to treatment, and will help more participants achieve abstinence from smoking, as indicated by a change in their smoking status from current to former smoking in their electronic health records. The comparison condition is a standard outreach approach comprising a mailed letter informing participants of person-to-person treatment options (quitline services, care from a primary care provider, and/or phone coaching and medication through a clinical trial).

Up to 12,000 adult participants who receive primary care at 10 participating clinic sites and whose electronic health records suggest they smoke will receive smoking cessation treatment outreach for up to 18 months, unless they opt out of participation. Randomization will occur at the clinic site level rather than at the participant level, and an opt-out approach to recruitment will be adopted.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Cluster-randomized controlledCluster-randomized controlled
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
BREATHE 2 Cluster-randomized Trial of Health System Changes to Increase Reach of Smoking Cessation Treatments
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Enhanced outreach

Quarterly outreach via letter and applicable patient-preferred modalities, including e-mail and/or text messaging, offering both standard person-to-person treatment options (quitline referral, primary care provider referral, cessation counseling and treatment in a randomized clinical trial) and self-guided, remote treatment options (mailed nicotine replacement therapy samples and/or facilitated enrollment in a Smokefree.gov texting program). Patients in clinics assigned to this arm will also have the option to initiate treatment by phone or online. Patients may also receive outreach calls from Tobacco Care Managers offering the person-to-person treatments at their health systems 1-30 days following a visit to a participating clinic.

Behavioral: Text message smoking treatment
Facilitated enrollment in an NCI-sponsored text messaging program: SmokefreeTXT (if ready to set a quit date in the next 14 days) Practice Quit (if ready to practice quitting 1-5 days but not ready to quit permanently) Daily Challenges (if not ready to quit, but willing to make some changes)

Drug: Nicotine replacement therapy sampling
Participants may request: Nicotine patches that release nicotine slowly over 24 hours, in either 7 mg, 14 mg, or 21 mg doses Nicotine gum or lozenges that release medication quickly and can be used every 1-2 hours to prevent and cope with cravings to smoke, in either 2 mg or 4 mg doses
Other Names:
  • Nicoderm, Nicorette
  • Combination Product: Wisconsin Tobacco QuitLine Referral
    Patients will be offered referral to the Wisconsin Tobacco QuitLine that offers phone counseling and nicotine replacement starter kits (2 week supplies) to people ready to quit smoking, in addition to web-based, text messaging, and mailed support, at no cost to Wisconsin residents.

    Combination Product: Referral to Primary Care Provider
    Patients who want to talk to their Primary Care Providers about quitting smoking will be encouraged to make an appointment with their provider to receive smoking cessation counseling and to discuss pharmacotherapy options.

    Combination Product: BREATHE 2 Cessation Study
    Patients who are interested in participating in a separate randomized controlled trial of smoking cessation treatment will be invited to learn about and complete an eligibility screening and consent process for the trial. Those who enter the study receive both counseling and pharmacotherapy.

    Behavioral: Additional modalities to learn about and request treatment
    Participants in Enhanced Outreach arm clinics will have the option to request e-mail and/or text message communication regarding their smoking treatment options, and to initiate treatment via phone or online survey.

    Active Comparator: Standard outreach

    One mailed letter at study initiation outlining available person-to-person treatment options (quitline referral, primary care provider referral, cessation counseling and treatment in a randomized clinical trial) and how to initiate treatment by phone. Patients may also receive outreach calls from Tobacco Care Managers offering the person-to-person treatments at their health systems 1-30 days following a visit to a participating clinic.

    Combination Product: Wisconsin Tobacco QuitLine Referral
    Patients will be offered referral to the Wisconsin Tobacco QuitLine that offers phone counseling and nicotine replacement starter kits (2 week supplies) to people ready to quit smoking, in addition to web-based, text messaging, and mailed support, at no cost to Wisconsin residents.

    Combination Product: Referral to Primary Care Provider
    Patients who want to talk to their Primary Care Providers about quitting smoking will be encouraged to make an appointment with their provider to receive smoking cessation counseling and to discuss pharmacotherapy options.

    Combination Product: BREATHE 2 Cessation Study
    Patients who are interested in participating in a separate randomized controlled trial of smoking cessation treatment will be invited to learn about and complete an eligibility screening and consent process for the trial. Those who enter the study receive both counseling and pharmacotherapy.

    Outcome Measures

    Primary Outcome Measures

    1. Smoking treatment initiation within 12 months of enrollment [Up to 12 months]

      The proportion of study participants who initiate smoking treatment, as recorded in the electronic health record. Rates of smoking treatment initiation will be compared in the Enhanced Outreach and Standard Outreach arms.

    Secondary Outcome Measures

    1. Smoking treatment initiation within 18 months of enrollment [Up to 18 months]

      The proportion of study participants who initiate smoking treatment, as recorded in the electronic health record. Rates of smoking treatment initiation will be compared in the Enhanced Outreach and Standard Outreach arms.

    2. Conversion from current smoking to former smoking [12 and 18 months after study enrollment]

      Quitting smoking as indicated by a change in smoking status from current to former smoking, as recorded in the electronic health record.

    3. Cost per quit attempt [Up to 18 months]

      Estimated costs per assisted quit attempt initiated will be computed.

    4. Cost per quit [Up to 18 months]

      Estimated costs per successful attempt (conversion to former smoking status) will be computed.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult age 18 years or older

    • Meet criteria for inclusion on a smoking registry (based on current smoking status and/or recent diagnosis of nicotine dependence or treatment of nicotine dependence)

    • Being seen in a participating clinic in the past 1-3 years, as documented in the EHR

    • Having a valid address

    • Not having a language other than English listed as preferred language

    Exclusion Criteria:
    • Invalid address

    • Participant opted out of the study within 18 months of initial outreach letter (or were opted out of the study by a legally authorized representative or an activated power of attorney for health care)

    • Participant clarification that they did not meet criteria for the smoking registry at the time of initial outreach

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Wisconsin, Madison
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Danielle E McCarthy, PhD, University of Wisconsin, Madison

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Wisconsin, Madison
    ClinicalTrials.gov Identifier:
    NCT05683821
    Other Study ID Numbers:
    • 2022-0973
    • 2P01CA180945-06
    • A534253
    • SMPH/MEDICINE/GEN INT MD
    • Protocol Version 07/11/2022
    First Posted:
    Jan 13, 2023
    Last Update Posted:
    Jan 13, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 13, 2023